Last updated: July 26, 2026
Novartis Pharmaceuticals Corporation sued Handa Neuroscience, LLC in the Northern District of Illinois under case number 1:21-cv-00645, filed in 2021. The docket indicates a patent-infringement dispute tied to a prescription neuroscience product, with outcomes that can materially affect later generic entry and distribution timelines.
What is the litigation background for Novartis Pharmaceuticals Corp v. Handa Neuroscience 1:21-cv-00645?
The case is a federal patent lawsuit in U.S. District Court for the Northern District of Illinois and is listed as Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, 1:21-cv-00645.
Parties and procedural posture
- Plaintiff: Novartis Pharmaceuticals Corporation
- Defendant: Handa Neuroscience, LLC
- Court / case no.: Northern District of Illinois, 1:21-cv-00645
- Filing year: 2021 (per docket metadata)
What type of IP dispute is it?
This docket number corresponds to a standard U.S. small-molecule/neuroscience patent infringement track typically paired with an ANDA (Paragraph IV) or a related FDA approval pathway dispute. In practice, these cases focus on whether the defendant’s proposed product infringes one or more of the Orange Book-listed patents asserted by the brand owner.
What patents does Novartis assert against Handa Neuroscience?
A complete, citation-grade mapping of asserted patent numbers (and which counts were pled for infringement) requires the specific complaint and claim chart text from the docket.
Because the asserted-claims set is not included in the provided material, a patent-by-patent, claim-by-claim summary cannot be produced here without risking factual error.
What claims and infringement theories are at issue in 1:21-cv-00645?
Patent infringement suits at this docket level typically plead combinations of:
- direct infringement of marketed or proposed dosage forms,
- induced infringement, and
- active inducement or contributory infringement depending on the claimed supply chain and product features.
A reliable claim-and-theory breakdown requires the complaint’s count structure, the specific product description, and the asserted claims.
No claim-count detail was provided in the prompt content, so a complete litigation-issues analysis cannot be generated accurately.
What is the status and outcome of the case (dismissal, settlement, trial, or appeal)?
A litigation-risk assessment for generic entry depends on end-state events:
- dismissal (with or without prejudice),
- stipulation of non-infringement finding,
- settlement with an agreed entry date or covenant terms,
- consent judgment,
- summary judgment,
- trial and final judgment,
- appellate disposition.
No case outcome metadata (orders, judgments, settlement documentation, or docket disposition) is included in the prompt content. A definitive status summary cannot be produced.
How does this litigation affect generic entry risk for Handa Neuroscience?
In Paragraph IV-style scenarios, the key commercial question is whether the court’s rulings or settlement create a launch trigger date, typically driven by:
- patent expiration,
- court stay status,
- settlement carve-outs (strength, dosage form, formulation),
- “design-around” work that avoids the asserted claim(s).
Without docket disposition, the analysis cannot be tied to an actual entry trigger, probability-weighted timeline, or enforceable injunction scope.
Which Orange Book patents are implicated, and what is their exclusivity timeline?
A proper Orange Book tie-in requires:
- the exact Novartis product name,
- the NDA/BLA number,
- the Orange Book patent list associated with that product (composition, method-of use, packaging, or manufacturing patents),
- the relevant expiration dates and regulatory exclusivities (NCE, pediatric, 180-day exclusivity, patent term adjustments).
The prompt provides only the case caption and docket number. Without the product/NDA mapping and the Orange Book listing, a precise exclusivity and expiration timeline cannot be stated.
How strong is Novartis’s patent estate in this dispute?
A strength analysis typically includes:
- number of asserted patents and independent claims,
- remaining term on each asserted patent as of filing,
- prosecution history risks (claim scope limits),
- prior art landscape,
- typical claim construction outcomes in the district,
- injunction leverage and settlement history for the brand class.
A strength conclusion requires the asserted-claim set and remaining-term profile. Those details are not present in the provided prompt.
How does the litigation compare with other Novartis pharma patent cases in neuroscience?
Comparative analysis depends on:
- overlap of asserted patents across cases,
- repeated defendants and shared product descriptions,
- settlement patterns and typical agreed entry dates,
- judicial preferences in claim construction.
No cross-case dataset or docket outcomes were provided, so a comparative benchmark cannot be accurately computed.
What litigation documents typically matter for investors and licensing teams in 1:21-cv-00645?
For high-stakes decisions, teams usually mine:
- complaint (asserted patents, infringement theory),
- answer and counterclaims,
- claim construction order,
- motions to dismiss (venue, pleading sufficiency),
- summary judgment motions (invalidity, non-infringement),
- preliminary injunction/temporary restraining order filings (if any),
- trial briefs and expert reports,
- settlement notices under Rule 25 or docket entries,
- final judgment and any appeal notice.
The specific documents and timestamps are not supplied in the prompt content.
Key Takeaways
- Case identity: Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, Northern District of Illinois, 1:21-cv-00645 (filed 2021).
- Commercial impact path: This type of federal patent case can delay or reshape FDA-driven market entry for a competing product depending on whether it is tied to Orange Book-listed patents and whether it ends in settlement or judgment.
- Missing case-specific substance: A patent-number level summary (asserted patents, claim scope, construction, and disposition) cannot be produced from the provided information without introducing error.
FAQs
1) Is Novartis v. Handa Neuroscience a Paragraph IV case?
Not determinable from the provided prompt content.
2) What patents were asserted by Novartis in 1:21-cv-00645?
Not determinable from the provided prompt content.
3) Did the court grant any injunction or stay in 1:21-cv-00645?
Not determinable from the provided prompt content.
4) What is the expected generic launch risk if Handa is attempting an ANDA?
Not determinable from the provided prompt content.
5) What is the Orange Book status of the Novartis product at issue?
Not determinable from the provided prompt content.
References (APA)
- Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, No. 1:21-cv-00645 (N.D. Ill. 2021).
